Patheon IncTSX: PTI

Update on CEPH International's FDA Warning Letter

· Issued by Patheon Inc via CNW
TORONTO, Sept. 27 /CNW/ - Patheon Inc. (TSX: PTI) today announced that
the Warning Letter received by its subsidiary, CEPH International Corporation
(CEPH), from the San Juan, Puerto Rico District office of the U.S. Food and
Drug Administration, (FDA) on September 16, 2005 has been posted on the FDA's
website at www.fda.gov.
As indicated in the Warning Letter, the affected product is powder for
oral suspension, Omnicef OP 250 mg/5mL and 125 mg/5mL. The issues identified
in the Warning Letter affect all manufacturing lines for the powder for oral
suspension product. The capsule product is not affected.
Patheon and CEPH are working diligently with their client to resolve the
issues identified by the FDA in the Warning Letter. CEPH has decided to
voluntarily suspend production of the powder product while it resolves these
matters. Patheon and CEPH are committed to working expeditiously to resolve
these issues so as to avoid interruption of supply of the product for the
client.

Patheon (TSX: PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical
Corporation, acquired in December 2004, Patheon operates a network of 14
facilities in the United States, Canada and Europe, employing more than 5,900
people and serving a client base of 180 pharmaceutical and biotechnology
companies.
%SEDAR: 00001700E

Patheon Inc on 6ix

In the deck

Earlier from Patheon

Later from Patheon

All Patheon news releases